Skip to content

Zymeworks ZYME Current State And Local Tax Expense Benefit

Current State And Local Tax Expense Benefit at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$2.43M-20.1%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$875.5K+213%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:CurrentStateAndLocalTaxExpenseBenefit.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's current state and local tax expense benefit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's current state and local tax expense benefit?
Zymeworks (ZYME) reported current state and local tax expense benefit of $3.75K in Q4 2025.
What does current state and local tax expense benefit mean?
The income tax expense or benefit incurred at the state or local jurisdictional level for the current period. This metric reflects the tax impact of operating in specific regional jurisdictions within the country. It helps investors understand the geographic tax footprint of the company's operations.